SCHEMBL133904

SCHEMBL133904

c1cncc(C2CCCCC2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 1/20 1.00
CHRNB2 P17787 6/20 0.58
CHRNA4 P43681 6/20 0.58
CHRNA7 P36544 5/20 0.58
CYP2A6 P11509 3/20 0.58
MEN1 O00255 2/20 0.58
CYP2D6 P10635 2/20 0.58
CYP2C19 P33261 2/20 0.58
KMT2A Q03164 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
POLB P06746 1/20 0.58
CYP1A2 P05177 1/20 0.58
CYP2C9 P11712 1/20 0.58
LMNA P02545 2/20 0.51
NAMPT P43490 1/20 0.51
TSHR P16473 1/20 0.51
HTT P42858 1/20 0.51
ALDH1A1 P00352 3/20 0.50
CHRNB4 P30926 2/20 0.50
CHRNA3 P32297 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23873927 1.00 CYP11B2 (1.00) CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6
SCHEMBL14029295 1.00 CYP11B2 (1.00) CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6
SCHEMBL6095783 0.98 CYP11B2 (0.96) CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6
SCHEMBL30434052 0.94 CYP11B2 (0.88) CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6
SCHEMBL26154135 0.94 CYP11B2 (0.88) CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6
SCHEMBL29848157 0.89
SCHEMBL990213 0.89
Cyanide SCHEMBL28217286 0.88 CYP11B2 (0.79) CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6
Formic Acid SCHEMBL28324256 0.87 CYP11B2 (0.77) CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6
Ammonia Solution, Strong SCHEMBL28985148 0.87 CYP11B2 (0.77) CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108802211-B Liquid phase detection method for related substances in cefquinome sulfate breast injectant 佛山市南海东方澳龙制药有限公司 2021-03-19 CN claimed
CN-108802212-B Liquid phase detection method for cefquinome sulfate breast injectant-related substances in lactation period 佛山市南海东方澳龙制药有限公司 2021-02-26 CN claimed
CN-111499566-A Pyridine derivative compound and preparation method thereof 南京工业大学 2020-08-07 CN claimed
CN-101787038-B Preparation method of cefquinome sulfate LUOYANG PU LINK BIO ENGINEERING CO LTD 2013-04-10 CN claimed
CN-101787038-A Preparation method of cefquinome sulfate LUOYANG PU LINK BIO ENGINEERIN 2010-07-28 CN claimed
EP-4318630-B1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS SECONDARY BATTERY ASAHI CHEMICAL IND (JP) 2025-10-22 EP disclosed
US-12199280-B2 Non-aqueous secondary battery and non-aqueous electrolyte ASAHI KASEI KABUSHIKI KAISHA (JP) 2025-01-14 US disclosed
EP-4415105-A2 NON-AQUEOUS SECONDARY BATTERY AND NON-AQUEOUS ELECTROLYTE Asahi Kasei Kabushiki Kaisha (JP) 2024-08-14 EP disclosed
WO-2024133200-A1 P2X3 RECEPTOR ANTAGONISTS RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) 2024-06-27 WO disclosed
EP-4389746-A2 P2X3 RECEPTOR ANTAGONISTS Recordati Industria Chimica E Farmaceutica SPA (IT) 2024-06-26 EP disclosed
US-11999732-B2 P2X3 receptor antagonists RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) 2024-06-04 US disclosed
US-20240178452-A1 Nonaqueous Electrolyte Solution and Nonaqueous Secondary Battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2024-05-30 US disclosed
US-5364853-A Treatment of disorders associated with vascular, respiratory, gastrointestinal tract, urinary bladder or uterus smooth muscle contraction RHONE-POULENC RORER LIMITED (GB) 1994-11-15 US disclosed
EP-0510028-A1 THIOFORMAMIDE DERIVATIVES. RHONE POULENC RORER SA (FR) 1992-10-28 EP disclosed
EP-0377532-B1 THIOFORMAMIDE DERIVATIVES MAY AND BAKER LIMITED (GB) 1992-07-29 EP disclosed
US-5104883-A Cardiovascular, respiratory, gastrointestirol, urogenital disorders; baldness; premature labor MAY & BAKER LIMITED (GB) 1992-04-14 US disclosed
EP-0377532-A1 Thioformamide derivatives MAY AND BAKER LIMITED (GB) 1990-07-11 EP disclosed
EP-0140322-B1 POLYMER CATALYST TRANSDUCERS AND USE THEREOF IN TEST KITS FOR ANALYTICAL METHODS MILES INC. (US) 1989-01-25 EP disclosed
US-4560534-A Polymer catalyst transducers MILES LABORATORIES, INC. (US) 1985-12-24 US disclosed
EP-0140322-A2 Polymer catalyst transducers and use thereof in test kits for analytical methods MILES INC. (US) 1985-05-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12199280-B2 Non-aqueous secondary battery and non-aqueous electrolyte CLK2, TYK2, CLK3 CYP11B2 3146/4885CHRNB2 748/4885CHRNA4 1620/4885
US-11999732-B2 P2X3 receptor antagonists P2RX3, P2RX5, P2RX2 CYP11B2 2813/4885CHRNB2 358/4885CHRNA4 337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.